Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
BLTE
Stock Latest News
The Fly
Belite Bio management to meet wit Cantor
5d ago
BLTE
Premium
Ratings
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks
12d ago
BLTE
Premium
Company Announcements
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
13d ago
6K
BLTE
Premium
The Fly
Belite Bio initiates rolling submission of NDA to U.S FDA for tinlarebant
13d ago
BLTE
Premium
Company Announcements
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
1M ago
BLTE
Premium
Company Announcements
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
1M ago
6K
BLTE
Premium
Company Announcements
Belite Bio Eyes 2027 Launch After Pivotal Win
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $200 from $185 at H.C. Wainwright
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $217 from $187 at Benchmark
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $201 from $191 at Morgan Stanley
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $200 from $195 at BofA
2M ago
BLTE
Premium
Ratings
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
2M ago
BLTE
Premium
The Fly
Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
2M ago
GD
VG
Premium
Company Announcements
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
2M ago
6K
BLTE
Premium
The Fly
Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)
2M ago
BLTE
Premium
The Fly
Belite Bio sees FY25 adjusted EPS ($1.15) vs. ($89c) last year
2M ago
BLTE
Premium
Pre-Earnings
Is BLTE a Buy, Before Earnings?
2M ago
BLTE
Premium
The Fly
Belite Bio price target raised to $223 from $194 at Mizuho
2M ago
BLTE
Premium
Company Announcements
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease
3M ago
6K
BLTE
Premium
The Fly
Belite Bio completes enrollment in DRAGON II trial of tinlarebant
3M ago
BLTE
Premium
The Fly
Netflix, Meta upgraded: Wall Street’s top analyst calls
3M ago
AAP
AIR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
